NCT07077278View on ClinicalTrials.gov

Effect of Low Sodium Oxybate (LXB) on Autonomic Symptom Burden in Idiopathic Hypersomnia Patients With Postural Tachycardia Syndrome

PHASE4Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

September 30, 2027

Study Completion Date

September 30, 2027

Conditions

Idiopathic HypersomniaPOTS - Postural Orthostatic Tachycardia Syndrome

Interventions

DRUG

Low sodium oxybate (LXB)

Participants will continue take low sodium oxybate (LXB) for two weeks after completing an open-label titration and dose optimization period of low sodium oxybate (LXB).

DRUG

Placebo

Participants will take placebo for two weeks after completing an open-label titration and dose optimization period of low sodium oxybate (LXB).

All Listed Sponsors

lead

Stanford University

OTHER